Yael Margolin Form 3/A BiondVax Pharmaceuticals / YAEL MARGOLIN ownership change

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:	3235-0104
Estimated average burden
hours per response:	0.5

1. Name and Address of Reporting Person^*

MARGOLIN YAEL

(Last) (First) (Middle)

JERUSALEM BIOPARK, 2ND FLOOR

HADASSAH EIN KEREM CAMPUS

(Street)

JERUSALEM L3 9112001

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
01/01/2023

3. Issuer Name and Ticker or Trading Symbol
BiondVax Pharmaceuticals Ltd. [ BVXV ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

5. If Amendment, Date of Original Filed (Month/Day/Year)
01/03/2023

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary Shares(2)	66,800	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options (right to buy)	(1)	11/19/2029	Ordinary Shares(2)	720,000	0.182	D
Stock Options (right to buy)	(3)	04/06/2031	Ordinary Shares(2)	1,000,000	0.174	D
Restricted Share Units	(4)	04/06/2031	Ordinary Shares(2)	133,200	(5)	D

Explanation of Responses:

1. Stock options were granted on March 24, 2020 and are fully vested.

2. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents four hundred Ordinary Shares.

3. Stock options were granted on April 6, 2021 and vest on a monthly basis during a period of three years.

4. Restricted share units were granted on April 6, 2021 and vest on a monthly basis during a period of three years.

5. Each restricted share unit represents a contingent right to receive one ordinary share.

	/s/ Yael Margolin	01/23/2023
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.